{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:00:02Z","timestamp":1774008002666,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM041935"],"award-info":[{"award-number":["R01 GM041935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006444","name":"M-CERSI","doi-asserted-by":"publisher","award":["1U01FD005946"],"award-info":[{"award-number":["1U01FD005946"]}],"id":[{"id":"10.13039\/100006444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejps.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T01:30:19Z","timestamp":1487899819000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay"],"prefix":"10.1016","volume":"103","author":[{"given":"Izna","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Swaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim L.R.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.02.011_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0306-9877(86)90137-4","article-title":"Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids","volume":"19","author":"Attili","year":"1986","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejps.2017.02.011_bb0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/mol.113.091314","article-title":"A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4\/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII)","volume":"86","author":"Banerjee","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.011_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/j.1572-0241.2006.00695.x","article-title":"Identification of a novel 974C-->G nonsense mutation of the MRP2\/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids","volume":"101","author":"Corpechot","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2017.02.011_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/jhep.2001.26213","article-title":"Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver","volume":"34","author":"Donner","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejps.2017.02.011_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0707305","article-title":"In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling","volume":"152","author":"Ekins","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.011_bb0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/toxsci\/kfs298","article-title":"Mechanisms of hepatocellular toxicity associated with dronedarone \u2014 a comparison to amiodarone","volume":"131","author":"Felser","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2017.02.011_bb0050","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s11095-008-9597-0","article-title":"Use of Tc-99m Mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies","volume":"25","author":"Ghibellini","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.02.011_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/ci050374h","article-title":"Enrichment of high-throughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and Laplacian-modified naive Bayesian classifiers","volume":"46","author":"Glick","year":"2006","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejps.2017.02.011_bb0060","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1074\/jbc.275.4.2905","article-title":"ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3)","volume":"275","author":"Hirohashi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2017.02.011_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/15748863113089990031","article-title":"Severe toxic hepatitis associated with dronedarone","volume":"8","author":"Jahn","year":"2013","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ejps.2017.02.011_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","article-title":"Drug-induced liver disorders: implications for drug development and regulation","volume":"24","author":"Kaplowitz","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejps.2017.02.011_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.113.055772","article-title":"Special section on transporters in toxicity and disease\u2014minireview the roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. DRUG Metab. Dispos","volume":"42","author":"Keppler","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0080","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2017.02.011_bb0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/dmd.113.054304","article-title":"Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4","volume":"42","author":"K\u00f6ck","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.510290404","article-title":"Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane","volume":"29","author":"K\u00f6nig","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.ejps.2017.02.011_bb0095","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2017.02.011_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00008571-200404000-00001","article-title":"Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3\/ABCC3)","volume":"14","author":"Lee","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2017.02.011_bb0105","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.107.124768","article-title":"A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2)","volume":"323","author":"Matsson","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.02.011_bb0110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","article-title":"Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development","volume":"118","author":"Morgan","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2017.02.011_bb0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2017.02.011_bb0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/toxsci\/kft197","article-title":"Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP\/ABCB11)","volume":"136","author":"Pedersen","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2017.02.011_bb0125","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/jm7015683","article-title":"Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)","volume":"51","author":"Pedersen","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2017.02.011_bb0130","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/1087057105281365","article-title":"Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up","volume":"10","author":"Rogers","year":"2005","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ejps.2017.02.011_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules","volume":"29","author":"Russel","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2017.02.011_bb0140","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl."},{"key":"10.1016\/j.ejps.2017.02.011_bb0145","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/dmd.114.061705","article-title":"Multidrug resistance-associated protein 3 plays an important role in protection against acute toxicity of diclofenac","volume":"43","author":"Scialis","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0150","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0016-5085(98)70026-5","article-title":"Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats","volume":"115","author":"Seitz","year":"1998","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.ejps.2017.02.011_bb0155","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.2337\/dc09-S355","article-title":"Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration","volume":"32","author":"Staels","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejps.2017.02.011_bb0160","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.02.011_bb0165","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis","volume":"51","author":"Wagner","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejps.2017.02.011_bb0170","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1124\/dmd.112.047068","article-title":"Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification","volume":"40","author":"Warner","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/dmd.114.062539","article-title":"Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors","volume":"43","author":"Welch","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.02.011_bb0180","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2017.02.011_bb0185","series-title":"Classification of kinase inhibitors using a Bayesian model","author":"Xia","year":"2004"},{"key":"10.1016\/j.ejps.2017.02.011_bb0190","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1021\/bi9001908","article-title":"Functional reconstitution of human ABCC3 into Proteoliposomes reveals a transport mechanism with positive cooperativity","volume":"48","author":"Zehnpfennig","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2017.02.011_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J. Hepatol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717300738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717300738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T22:57:20Z","timestamp":1536015440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717300738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":38,"alternative-id":["S0928098717300738"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.02.011","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}